ATE397458T1 - Neue heilmittel für krebs - Google Patents
Neue heilmittel für krebsInfo
- Publication number
- ATE397458T1 ATE397458T1 AT01954360T AT01954360T ATE397458T1 AT E397458 T1 ATE397458 T1 AT E397458T1 AT 01954360 T AT01954360 T AT 01954360T AT 01954360 T AT01954360 T AT 01954360T AT E397458 T1 ATE397458 T1 AT E397458T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- new cure
- cure
- new
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000228239 | 2000-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE397458T1 true ATE397458T1 (de) | 2008-06-15 |
Family
ID=18721568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01954360T ATE397458T1 (de) | 2000-07-28 | 2001-07-26 | Neue heilmittel für krebs |
Country Status (13)
Country | Link |
---|---|
US (3) | US7449181B2 (de) |
EP (1) | EP1308168B1 (de) |
JP (1) | JP5117660B2 (de) |
KR (1) | KR20030019623A (de) |
CN (2) | CN100581585C (de) |
AT (1) | ATE397458T1 (de) |
AU (1) | AU2001276689A1 (de) |
CA (1) | CA2417255C (de) |
DE (1) | DE60134324D1 (de) |
DK (1) | DK1308168T3 (de) |
ES (1) | ES2307633T3 (de) |
TW (1) | TWI317285B (de) |
WO (1) | WO2002009754A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7625859B1 (en) * | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
MXPA02011379A (es) * | 2000-05-19 | 2003-06-06 | Genentech Inc | Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb. |
ES2381408T3 (es) * | 2002-03-18 | 2012-05-28 | Dainippon Sumitomo Pharma Co., Ltd. | Remedios para el cáncer de pulmón. |
FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
CA2583230A1 (en) * | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
CN100464783C (zh) * | 2004-11-22 | 2009-03-04 | 山东蓝金生物工程有限公司 | 一种含抗肿瘤抗生素的抗癌药物组合物 |
KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
UA95902C2 (ru) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
ES2477497T3 (es) | 2007-03-02 | 2014-07-17 | Genentech, Inc. | Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo |
EP2171090B1 (de) * | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Genexpressionsmarker für tumorresistenz gegen behandlung mit her2-inhibitor |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
UA106070C2 (uk) | 2009-03-20 | 2014-07-25 | Дженентек, Інк. | Антитіло, що специфічно зв'язується з egfr і her3 |
JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター |
SG183333A1 (en) | 2010-02-18 | 2012-09-27 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (de) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispezifische moleküle |
EP2655413B1 (de) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung |
EP2744824A1 (de) | 2011-08-17 | 2014-06-25 | F.Hoffmann-La Roche Ag | Neuregulin-antikörper und verwendungen davon |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
SG11201406079TA (en) | 2012-03-27 | 2014-10-30 | Genentech Inc | Diagnosis and treatments relating to her3 inhibitors |
MX363188B (es) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1. |
EP3454863A1 (de) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Kombinationstherapien zur behandlung von krebs |
CN107349426B (zh) * | 2017-07-12 | 2018-03-23 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6075473A (ja) * | 1983-09-30 | 1985-04-27 | Sumitomo Chem Co Ltd | アミノナフタセン誘導体 |
US5185432A (en) * | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5077220A (en) * | 1988-08-26 | 1991-12-31 | John Muir Cancer & Aging Institute | Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells |
JPH035397A (ja) | 1989-05-31 | 1991-01-11 | Toshiba Corp | 酸化物結晶薄膜の気相成長方法 |
JP3005397B2 (ja) | 1993-09-06 | 2000-01-31 | 関西日本電気ソフトウェア株式会社 | デッドロック多発自動回避方式 |
US5686278A (en) * | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
CN1164238A (zh) * | 1994-09-12 | 1997-11-05 | 国际生物免疫有限公司 | 抗人结肠癌相关抗原的单克隆抗体及其应用 |
CZ291386B6 (cs) * | 1996-02-13 | 2003-02-12 | Zeneca Limited | Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
CN1082187C (zh) * | 1996-11-26 | 2002-04-03 | 北京市肿瘤防治研究所 | 一种检测***受体水平的生物试剂及免疫组化方法 |
JP2002514201A (ja) * | 1997-01-22 | 2002-05-14 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 凝固および腫瘍の処置のための組織因子の方法および組成物 |
US20030068318A1 (en) * | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
-
2001
- 2001-07-24 TW TW90118039A patent/TWI317285B/zh not_active IP Right Cessation
- 2001-07-26 DK DK01954360T patent/DK1308168T3/da active
- 2001-07-26 CN CN01816215A patent/CN100581585C/zh not_active Expired - Fee Related
- 2001-07-26 CN CN2009102523811A patent/CN101732333B/zh not_active Expired - Fee Related
- 2001-07-26 AT AT01954360T patent/ATE397458T1/de active
- 2001-07-26 KR KR10-2003-7001194A patent/KR20030019623A/ko not_active Application Discontinuation
- 2001-07-26 CA CA 2417255 patent/CA2417255C/en not_active Expired - Fee Related
- 2001-07-26 WO PCT/JP2001/006467 patent/WO2002009754A1/ja active IP Right Grant
- 2001-07-26 JP JP2002501211A patent/JP5117660B2/ja not_active Expired - Lifetime
- 2001-07-26 DE DE60134324T patent/DE60134324D1/de not_active Expired - Lifetime
- 2001-07-26 ES ES01954360T patent/ES2307633T3/es not_active Expired - Lifetime
- 2001-07-26 EP EP20010954360 patent/EP1308168B1/de not_active Expired - Lifetime
- 2001-07-26 AU AU2001276689A patent/AU2001276689A1/en not_active Abandoned
- 2001-07-26 US US10/333,978 patent/US7449181B2/en not_active Expired - Fee Related
-
2007
- 2007-06-11 US US11/761,264 patent/US7879327B2/en not_active Expired - Fee Related
-
2010
- 2010-12-23 US US12/978,275 patent/US9139658B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TWI317285B (en) | 2009-11-21 |
JP5117660B2 (ja) | 2013-01-16 |
US7449181B2 (en) | 2008-11-11 |
CN100581585C (zh) | 2010-01-20 |
US9139658B2 (en) | 2015-09-22 |
AU2001276689A1 (en) | 2002-02-13 |
CN1466464A (zh) | 2004-01-07 |
DK1308168T3 (da) | 2008-07-28 |
US20080031881A1 (en) | 2008-02-07 |
CN101732333B (zh) | 2012-08-15 |
US7879327B2 (en) | 2011-02-01 |
CA2417255C (en) | 2011-08-02 |
CA2417255A1 (en) | 2003-01-24 |
US20110104160A1 (en) | 2011-05-05 |
ES2307633T3 (es) | 2008-12-01 |
EP1308168B1 (de) | 2008-06-04 |
US20030157097A1 (en) | 2003-08-21 |
DE60134324D1 (de) | 2008-07-17 |
WO2002009754A1 (fr) | 2002-02-07 |
EP1308168A1 (de) | 2003-05-07 |
EP1308168A4 (de) | 2004-09-01 |
KR20030019623A (ko) | 2003-03-06 |
CN101732333A (zh) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE397458T1 (de) | Neue heilmittel für krebs | |
PT1196172E (pt) | (s,s)-reboxetina para tratar a dor cronica | |
CY1119029T1 (el) | Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης | |
DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
BR0012196A (pt) | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado | |
DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
IT1317735B1 (it) | Sali di agenti antimicrobici. | |
DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
PT1244650E (pt) | Derivados arilaminas e sua aplicacao como agentes anti-telomerase | |
PT1401841E (pt) | Derivados substituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno como medicamentos para o tratamento da dor | |
ES2156603T3 (es) | Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina. | |
GB0019283D0 (en) | Organic compounds | |
EE04752B1 (et) | Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine | |
ATE430586T1 (de) | Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743 | |
BRPI0418589A (pt) | composições farmacêuticas e métodos para tratamento por insulina | |
DK1465625T3 (da) | Opløste topoisomerase-gifte | |
GB0008305D0 (en) | Treatment of fungal infections | |
NO20053339D0 (no) | Levalbuterolsalt. | |
EP1354896A4 (de) | Neuer monoklonaler antikörper | |
CY1105142T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
DE60315288D1 (de) | Cyanoguanidin prodrugs | |
EE200300082A (et) | Farmatseutilne kompositsioon urineerimishäire raviks | |
EE200200605A (et) | Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1308168 Country of ref document: EP |